How to improve prostate biopsy detection of prostate cancer.
The combination of serum prostate-specific antigen (PSA) testing and transrectal ultrasonography is a highly effective strategy to diagnose prostate cancer at an early curable stage. Even though PSA is the most useful serum biomarker to aid in prostate cancer detection, it has limited specificity: as many as 75% of men who undergo prostate biopsy because of an elevated PSA do not have prostate cancer. Additionally, sextant prostate biopsies miss prostate cancer at least 20% of the time. To reduce the number of false-negative biopsies, many have advocated obtaining 12 or more cores in a single biopsy session. Studies have shown that this practice is safe and can enhance cancer detection modestly. Although it is unlikely that prostate cancer imaging will replace prostate biopsy in the near future, many exciting new imaging technologies should eventually improve targeting of prostate needle biopsy and reduce false-negative biopsies. Some of the most exciting areas include power Doppler sonography, microbubble intravenous ultrasound contrast agents, and magnetic resonance spectroscopy. These functional imaging modalities can assess tumor blood flow and metabolic activity at a cellular level and can detect malignant changes that may not be detected by standard anatomic imaging.
Ornstein
D K
DK
Department of Surgery/Division of Urology, The University of North Carolina at Chapel Hill, 427 Burnett-Womack Building CB, #7235, Chapel Hill, NC 27599-7235, USA. ornstein@med.unc.edu
Kang
J
J
D001707:Biopsy, Needle; D003951:Diagnostic Errors / Q000517:prevention & control*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D012680:Sensitivity and Specificity